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Abstract
Background: Visceral Leishmaniasis (VL; also known as kala-azar) is an ultimately fatal disease endemic in the Indian state of
Bihar, while HIV/AIDS is an emerging disease in this region. A 2011 observational cohort study conducted in Bihar involving
55 VL/HIV co-infected patients treated with 20–25 mg/kg intravenous liposomal amphotericin B (AmBisome) estimated an
85.5% probability of survival and a 26.5% probability of VL relapse within 2 years. Here we report the long-term field
outcomes of a larger cohort of co-infected patients treated with this regimen between 2007 and 2012.
Methods and Principal Findings: Intravenous AmBisome (20–25 mg/kg) was administered to 159 VL/HIV co-infected
patients (both primary infections and relapses) in four or five doses of 5 mg/kg over 4–10 days. Initial cure of VL at discharge
was defined as improved symptoms, cessation of fever, improvement of appetite and recession of spleen enlargement. Test
of cure was not routinely performed. Antiretroviral treatment (ART) was initiated in 23 (14.5%), 39 (24.5%) and 61 (38.4%)
before, during and after admission respectively. Initial cure was achieved in all discharged patients. A total of 36 patients
died during follow-up, including six who died shortly after admission. Death occurred at a median of 11 weeks (IQR 4–51)
after starting VL treatment. Estimated mortality risk was 14.3% at six months, 22.4% at two years and 29.7% at four years
after treatment. Among the 153 patients discharged from the hospital, 26 cases of VL relapse were diagnosed during follow-
up, occurring at a median of 10 months (IQR 7–14) after discharge. After accounting for competing risks, the estimated risk
of relapse was 16.1% at one year, 20.4% at two years and 25.9% at four years. Low hemoglobin level and concurrent
infection with tuberculosis were independent risk factors for mortality, while ART initiated shortly after admission for VL
treatment was associated with a 64–66% reduced risk of mortality and 75% reduced risk of relapse.
Significance: This is the largest cohort of HIV-VL co-infected patients reported from the Indian subcontinent. Even after
initial cure following treatment with AmBisome, these patients appear to have much higher rates of VL relapse and
mortality than patients not known to be HIV-positive, although relapse rates appear to stabilize after 2 years. These results
extend the earlier findings that co-infected patients are at increased risk of death and require a multidisciplinary approach
for long-term management.
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Introduction
One third of all HIV patients worldwide live in regions where
leishmaniasis is endemic [1]. Visceral leishmaniasis (VL) caused by
the parasite L. donovani is endemic to Bihar, a populous state of
110 million people in East India, which carries an estimated 40%
of the world’s VL burden [2]. Although Bihar has a relatively low
prevalence of HIV (between 0.22–0.33%), its high population
density means that in absolute numbers an estimated 300,000
people in the state live with HIV/AIDS [3].
Moreover, Bihar is one of the few states in India where the rate
of new HIV infections is increasing [4]. This has major
implications for VL co-infection: like other opportunistic infections
in HIV patients, Leishmania amastigotes have evolved strategies to
survive and multiply within macrophages [5], which are enhanced
by HIV co-infection [6] and accelerate progression of disease [7].
This may help explain why the risk of developing VL is estimated
to be between 100 and 2300 times higher in HIV-infected
individuals than in those who are HIV-negative. [8]. Data on the
prevalence of HIV-VL co-infection in India is scarce, although
estimates range from 2–5.6% [9–14]. HIV-VL co-infection
therefore appears to be a growing public health issue in India.
Yet the evidence base regarding best treatment practices for co-
infected patients is limited, due to a lack of randomized controlled
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trials and to the fact that most available data comes from
observational studies with relatively short follow-up periods and
often with high rates of loss to follow-up [15]. Nevertheless, worse
outcomes in almost every respect have consistently been reported
in this patient group when compared to patients not known to be
HIV-positive—for example, in terms of higher relapse rates,
mortality, and VL drug toxicity and resistance [15].
Currently the Indian treatment guidelines for VL do not
differentiate treatment of HIV-VL co-infected patients from that
of other patients presenting with VL. First-line treatment for all
VL patients in India is 28 days of oral miltefosine (where not
contra-indicated), although the government is currently assessing
the use of single-dose AmBisome and lower-dose combinations
therapies [16] as recommended by the World Health Organiza-
tion (WHO) [17]. However, India has not developed a contin-
gency plan for HIV-VL patients.
Since 2007, Me´decins Sans Frontie`res (MSF) has collaborated
with the Rajendra Memorial Research Institute (RMRI) and the
National Vector Borne Disease Control Program (NVBDCP) to
implement a VL treatment program within Ministry of Health
(MoH) facilities in Vaishali district, one of the most highly endemic
areas for VL in Bihar, The program has treated over 8,500
patients using 20 mg/kg liposomal amphotericin B (AmBisome,
Gilead Pharmaceuticals, Foster City, CA, USA). High-dose
liposomal amphotericin B is currently recommended by WHO
for first-line treatment of HIV-VL co-infection [17]. We have
exclusively used AmBisome, a brand name for liposomal
amphotericin B, since it is the only preparation of this medication
that has received stringent regulatory approval for use in VL [16].
In this retrospective observational cohort study of routinely
collected program data, we describe the baseline characteristics of
the 159 HIV-VL co-infected patients treated with liposomal
amphotericin B in the Bihar program between July 2007 and
August 2012. We then describe the outcomes for VL immediately
after treatment and in the longer term (up to 5 years), the latter
being crucial to monitor given the chronic nature of HIV
infection.
Methods
In collaboration with RMRI, MSF developed a comprehen-
sive VL program that was fully integrated into the MoH
facilities in Vaishali district, Bihar. This program encompassed
two main activities: the running of an MSF-led inpatient unit
within the district hospital, and the provision of logistic support
for VL services to five Primary Health Centers (PHCs) within
Vaishali district. From February 2007 until August 2012, 8,749
patients were treated for VL using 20 mg/kg liposomal
amphotericin B as first-line therapy, as described in detail
elsewhere [18]. Approximately 50% of these patients originated
from Vaishali district, while the remainder travelled from
adjacent districts. Over time, rising numbers of patients entered
the program via referrals from neighbouring district hospitals.
In particular, HIV treatment centers outside the district
increasingly referred patients who had been diagnosed with
HIV and were thought to have VL. During the 5-year study
period, the VL program treated 159 HIV co-infected patients,
of whom 60 were directly referred by outside HIV treatment
centers (Figure 1).
Data collected for all patients diagnosed with VL included
general demographic information, clinical history, hemoglobin
level, height, weight, and malaria rapid diagnostic test result. The
study also recorded information on ‘caste’, a form of social
stratification used in India, using the following categories and
definitions: scheduled caste and scheduled tribe (terms used for
two groups of historically disadvantaged people recognized in the
Constitution of India); other backward class (a collective term used
by the government of India for castes that are educationally and
socially disadvantaged but not specifically mentioned in the
Constitution); and general category (not considered to be
disadvantaged). The first three groups combined account for
approximately 60% of India’s population.
Diagnosis of Visceral Leishmaniasis
All patients with a history of 2 weeks fever and clinical
splenomegaly were considered suspect for VL. Diagnosis was
confirmed with the rK39 rapid diagnostic test (DiaMed-IT
LEISH; DiaMed AG, Cressier, Switzerland). Patients presenting
with a history suggestive of relapse or with atypical clinical signs or
negative diagnostic tests but a high index of suspicion of VL were
referred to the RMRI for parasitological diagnosis through splenic
or bone marrow biopsy. Of the 159 co-infected patients, 31 had
the diagnosis of VL confirmed solely with rk39 serological testing,
with the remainder through parasitological visualization on biopsy
using established techniques [19].
Diagnosis of HIV
At the start of the program, only patients with a history
suggestive of possible HIV exposure were offered provider-
initiated counseling and testing (PICT) for HIV. Indications for
PICT included a history of relapse, a high-risk profession or being
a migrant worker, but were otherwise not clearly defined. Patients
self-reporting a previous diagnosis of HIV were counseled and re-
tested, as were patients referred from external hospitals present-
ing with a provisional diagnosis of HIV-VL co-infection.
However, a few patients treated for VL and discharged from
the program subsequently re-presented with confirmed relapse, at
which point they were tested and diagnosed with HIV infection.
Therefore, the HIV testing policy was changed in March 2011,
after which all patients aged $14 years were offered PICT for
HIV.
Author Summary
Fifty percent of all visceral leishmaniasis (VL) cases globally
occur in India, where up to 90% of cases occur in the state
of Bihar. There are also an estimated 300,000 people in
Bihar living with HIV/AIDS. Patients with HIV who are
treated for VL typically have much worse outcomes than
VL patients who are HIV-negative, yet there exists very
little evidence suggesting more effective treatments for
this group. Between 2007–2012, with support of the
Rajendra Memorial Research Institute (RMRI), Me´decins
Sans Frontie`res (MSF) treated 8,749 VL patients in Bihar
using liposomal amphotericin-B (AmBisome). Here we
describe the characteristics and long-term outcomes of a
subgroup of 159 HIV-VL co-infected patients treated within
this program over the 5-year period. Their estimated
mortality risk was 14.3% at six months after treatment,
22.4% at two years and 29.7% at four years. Estimated risk
of relapse was 16.1% at one year, 20.4% at two years and
25.9% at four years. We conclude that treatment of HIV-VL
co-infected patients with 20–25 mg/kg of liposomal am-
photericin-B is well tolerated and relatively effective.
However, HIV-VL co-infection is a complex chronic disease
with high early mortality and much worse outcomes than VL
alone, and requires a multidisciplinary long-term manage-
ment strategy.
Long-term Outcomes of AmBisome for HIV-VL Co-infection in India
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HIV testing at the program facility was initially performed
using two rapid diagnostic tests in parallel (SD Bioline HIV 1/2
and Determine-HIV 1/2), with patients testing positive referred
to MoH testing facilities for further diagnosis as per local
protocols using Combaids Advantage, TriLine and TriSpot
RDTs. However, use of SD Bioline was stopped in December
2011, in keeping with WHO recommendations [20]. From that
point onwards, patients testing positive with Determine-HIV 1/2
tests alone were referred. Discordant tests were confirmed with
Western Blot.
Figure 1. Patient characteristics and flow through VL treatment. Footnote: *A total of 161 patients were diagnosed with HIV-VL co-infection
in the program. One HIV-VL patient died before any treatment was given, and another was diagnosed with HIV at an external facility 3 months after
completion of treatment. ** 1 patient was treated with total dose of 15 mg/kg due to pre-existing renal failure (included in analysis). *** 2 patients
who relapsed subsequently died. HIV – Human Immunodeficiency Virus, VL – Visceral Leishmaniasis, ART – Antiretroviral Therapy.
doi:10.1371/journal.pntd.0003053.g001
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Treatment and follow-up
Patients with or without HIV who presented to the program for
the first time were treated under the same protocol, using 20 mg/
kg intravenous liposomal amphotericin B given in 4 doses over 4–
10 days depending on the severity of illness. Patients considered to
be in good clinical condition were treated on 4 consecutive days,
while those requiring a longer period of inpatient observation
received the 4 doses over 10 days. All patients diagnosed with a
VL relapse and who had previously received the 20 mg/kg
liposomal amphotericin B regimen at the program were treated
with an increased dose (25 mg/kg) of liposomal amphotericin B
following parasitological confirmation of relapse. All patients
presenting with VL relapse were offered PICT, Patients were
considered ‘initial cures’ once they completed a full course of VL
treatment and showed clinical improvement, cessation of fever,
reduction of spleen size and return of appetite at the time of
discharge following WHO descriptions of treatment response [21].
Test of Cure (ToC) was not routinely performed, due to the risks
associated with splenic puncture and in light of a previous study
showing a cure rate of .98% at 6 months [22], Instead, splenic or
bone marrow aspiration was reserved for confirmation of VL in all
patients presenting with relapse, those with suspected initial
treatment failure, and initially, for all HIV-VL co-infected
patients. However, as neither relapses nor treatment failures
occurred in any of the 55 HIV-VL patients treated during the first
6 months, [23], from that point onwards ToC was not routinely
performed in this group.
Following completion of VL treatment and improvement of
their general condition, patients with HIV–VL co-infection were
offered antiretroviral treatment (ART) at either the RMRI or
within Vaishali district hospital, using the national program-
recommended regimen of stavudine, lamivudine and nevirapine.
However, as a growing number of national program centers
providing ART opened in Bihar over time, responsibility for
initiation and maintenance of ART was transferred to these more
local facilities, which helped create a more sustainable, patient-
friendly treatment strategy. Communication between the VL
treatment program and the ART treatment centers was
maintained, and patients with suspected VL relapse were referred
back to the MSF program for diagnosis and treatment. In
addition, the centers shared information on ART patient
adherence and CD4 counts, where available.
After successful completion of VL treatment, patients were
asked to return to the MSF program for follow-up at 1, 3, 6, 12
and 24 months from the time of VL treatment initiation, They
were also counseled at discharge regarding the high risk of relapse
and the importance of adherence to ART. Secondary prophylaxis
against VL, which is recommended elsewhere [8,17], was not
offered. The program made considerable effort to maintain long-
term contact with patients though active telephone tracing and, in
cases where contact through telephone tracing or ART treatment
centers failed, through home visits.
Data collection
All data were entered into a standard Microsoft Excel database;
double data-entry was not done at the time of inputting. Regular
database cleaning consisted of checks for inconsistencies, with
reference to source documents where necessary. Although an
epidemiologist ensured the database was well maintained and
regularly audited the quality of data transfer, all records of co-
infected patients were reviewed again immediately before the final
analysis to ensure that data entered into the database was correct.
Nutritional status (Body Mass Index, BMI) was assessed using
weight and height data for patients $19 years of age, while World
Health Organization Anthro and Anthro Plus software (Geneva,
Switzerland) was used to calculate a BMI-for-age Z-score for those
aged $5–19 years and Weight for Height (W/H) Z-score for those
6 months to ,5 years of age. For patients $19 years of age, severe
acute malnutrition (SAM) and moderate acute malnutrition
(MAM) were defined as BMI,16 and 16–,17, respectively. For
patients aged $5–19 years, SAM was defined as BMI-for-age Z-
score ,23 and MAM as ,22 but .23 SD, while for patients
aged 6 months–,5 years, SAM and MAM were defined as W/H
Z-score ,23 and ,22 but .23 SD, respectively.
Data analysis
Statistical analysis of data was conducted using STATA version
11 (STATACorp LP, College Station, USA). For the final analysis
all data were anonymised. Baseline characteristics for all co-
infected patients were compared against VL patients not known to
be HIV-positive and treated in the program over the same time
period. Primary outcomes were time to death and time to relapse.
Person-time at risk was calculated for each patient, starting from
the date of VL treatment initiation up to the date of death, date of
the last visit (for those lost to follow-up), or 31st August 2013 (for
everyone else). With relapse as outcome, follow-up time started
with hospital discharge and ended at the date of (first) relapse for
those with relapse. The cumulative incidence of mortality or
relapse was estimated using Kaplan-Meier methods. A risk factor
analysis was performed using multivariate Cox regression model-
ling. Variables considered for inclusion were age, sex, a history of
VL, ART use and the following characteristics (all at the time of
VL diagnosis): hemoglobin level, body mass index, spleen size,
CD4 cell count, concurrent tuberculosis, and duration of illness
(only in relapse analysis).
For those initiating ART, the overall change in CD4 count
levels after diagnosis of HIV-VL co-infection was visualized using
a nonparametric method called LOWESS smoothing (for locally
weighted scatterplot smoothing, ‘lowess’ command in STATA).
This provides a representative smooth curve through data using
robust local regression.
In the mortality analysis, ART use was categorized as either 1)
being on ART at the time of VL diagnosis, or 2) ART initiation
after VL diagnosis, included as a time-varying covariate. With
relapse as outcome, ART use was categorized as 1) being on ART
at the time of VL diagnosis; 2) ART initiation during admission: 3)
ART initiation sometime after admission, included as a time-
varying covariate. In the main analysis, variables associated with
the outcome with a P-value ,0.05 in univariate analysis were
included in multivariate analysis. The model was reduced by
backward stepwise elimination until all variables had a P-value
,0.05. In secondary analysis, ART use was forced in the model.
In the main analysis, multiple imputation was used for missing
data [24]. In sensitivity analysis 1, we used the missing indicator
method (whereby for a specific predictor a separate category is
generated for missing data). Continuous co-variables were
categorized in the main analysis but included as continuous
variables in sensitivity analysis 2, with the functional form
determined using the multivariable fractional polynomial (mfp)
models command in STATA. Several other secondary and
sensitivity analyses were also conducted, including the removal
of patients with incomplete information on ART use in models
involving this parameter.
In addition, the cumulative incidence of relapse was recalcu-
lated to allow for the presence of competing risks (death precluding
the occurrence of relapse), since in this case standard survival
methods can lead to biased estimates [25,26]. The proportional
hazard assumption was assessed graphically and tested formally
Long-term Outcomes of AmBisome for HIV-VL Co-infection in India
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using Schoenfeld residuals. Co-linearity was evaluated by calcu-
lating the variance inflation factors. The level of significance was
set at P,0.05.
Ethics statement
This analysis met the Me´decins Sans Frontie`res Institutional
Ethics Review Committee criteria for a study involving the
analysis of routinely collected program data. Although AmBisome
is a new treatment in the Indian setting, it is a recognized
treatment for VL; moreover, the program was run in coordination
with the State Health Society through a memorandum of
understanding, which is the usual procedure for NGOs operating
in this context. The HIV-VL clinical treatment guideline had been
reviewed and approved by the RMRI Institutional Ethics
Committee. All electronic data were analyzed anonymously.
Results
A total of 159 HIV/VL co-infected patients were treated for VL
during the 5-year MSF-supported program (July 2007 to August
2012). Of these, 150 (94.3%) were treated with 20 mg/kg
liposomal amphotericin B, while 8 (5%) were treated with a
25 mg/kg regimen. All patients completed treatment with no
discontinuations or serious adverse events, and no deaths were
associated with liposomal amphotericin B treatment. Four patients
were lost to follow up within one month after VL diagnosis, one at
six months and one at twelve months. The maximum length of
follow-up was 5.6 years following completion of VL treatment,
with a mean of 2 and median of 1.2 years.
Patient characteristics
The demographic and baseline clinical characteristics of the 159
co-infected patients compared to the remaining treated cohort of
8,590 patients not known to be HIV-positive are shown in
Table 1. The Relative Risk (RR) of being HIV-positive was 3.7
times higher for males than for females, while the RR of being
HIV-positive was 25 times lower (0.04, 0.02–0.07) for patients
,25 years of age compared to those aged 25–,55 years. The
mean 6SD age was 36.6610.4 years (range 7–70); 145 (91.2%)
patients were aged 25–55 years, of whom 64 (44.1%) were aged
35–45 (Table 1). The RR of being co-infected with HIV and of a
General Category caste was 2.2 (95% Confidence Interval 1.6–3.1)
times higher than compared to being of an Other Backward Class
or Scheduled Caste. Compared to patients not known to be HIV-
positive, those with HIV-VL co-infection tended to have a lower
hemoglobin (,6 g/dl) on admission (RR 1.7, 1.02–2.7, p= 0.04)
and a greater degree of splenomegaly .6 cm (RR 2.1, 1.6–2.9,
p,0.001).
There was no significant difference between the global
nutritional status of patients known to be HIV-positive and the
remainder of the cohort (43.3% vs 40.8% globally malnourished
respectively, RR (95%CI) = 1.1 (0.8–1.5), p = 0.54), nor was there
a significant difference in the prevalence of severe acute
malnutrition (SAM) between patients known to be HIV-positive
and the remainder of the cohort – 23.9% vs 17.9%, respectively,
RR=1.4 (95%CI 0.95–2.0, p = 0.095).
However, the RR of presenting with a relapse of VL was
particularly high – the odds of being HIV-positive and having
previously experienced a single or multiple episodes of VL prior to
admission was 16.6 times higher than in the overall cohort (95%
CI 12.4–22.4; p,0.001).
Of the 159 co-infected patients, 60 (37.7%) had been diagnosed
with HIV prior to attending the MSF program, of which less than
half (23) were receiving ART at time of diagnosis of VL. The
remaining 99 (62.3%) patients were diagnosed with HIV at the
time of VL diagnosis. 122 (76.7%) of patients had CD4 counts
recorded between 6 months before or one month following
treatment for VL, with a mean count of 122 cells/uL, and a
median of 111 (IQR 59-193). Nearly half (n = 56, 46%) had counts
,100 cells/uL. Patients already on ART at time of treatment for
VL had a median CD4 count of 188 cells/ul (IQR 54-164), while
patients not on ART had a median CD4 count of 101 cells/ul
(IQR 75-234). Patients presenting with primary or a previous
episode of VL had a median CD4 counts of 108 cells/uL (IQR 57-
163) and 113 cells/uL (IQR 61-216) respectively. A total of 9
(5.7%) patients were suffering from tuberculosis in addition to
HIV-VL co-infection.
Survival
A total of 36 co-infected patients died, including six who died
shortly after admission. Death occurred at a median of 11 weeks
(Inter-Quartile Range, IQR 4-51) after starting VL treatment. The
estimated mortality risk was 14.3% at six months, 22.4% at two
years and 29.7% at four years after diagnosis (Figure 2). In
univariate analysis, a low BMI (,16 kg/m2), low hemoglobin
(,7 g/dL) at admission, and concurrent tuberculosis were each
associated with an increased risk of mortality (Table 2). Use of
ART was associated with a decreased risk.
In multivariate analysis, concurrent tuberculosis and low
hemoglobin were independent risk factors. This remained true
when ART use was included the model. ART use was associated
with a 64–66% reduced risk of mortality, but the effect only
reached statistical significance when ART was initiated after VL
diagnosis (Table 3). Minor changes in the estimates were observed
in the sensitivity analyses.
VL treatment response
Although all patients completed treatment and showed clinical
improvement, six patients died following a period of prolonged
admission, likely due to multiple contributing factors. From the
remainder, there were no documented cases of treatment failure
based on treatment response. Among the 153 patients discharged
from the hospital, a total of 26 cases of VL relapse were diagnosed
during follow-up, occurring at median of 10 months (IQR 7-14)
after discharge. The estimated risk of relapse was 1.6% at six
months after discharge, but subsequently increased to 18.5% at
one year and 23.8% at two years (Figure 3). Four years following
VL treatment the risk was 31.2%.
In univariate analysis, age .40 years was associated with an
increased risk of relapse (Table 4). This effect showed borderline
significance when ART use was included in the model. The
association of ART use with a reduced risk of relapse (75%
reduction) was statistically significant only for ART initiation
during admission.
We also examined whether CD4 cell count recovery following
VL treatment was associated with the risk of relapse. As shown in
Figure 4, CD4 recovery was blunted in patients who subsequently
relapsed compared to those who remained relapse-free. The
median CD4 count of patients who relapse and did not
subsequently relapse following treatment was 95 cells/uL, (IQR
63-163) versus 112 cells/uL, (IQR 57-206), respectively. Of the 26
patients who subsequently relapsed, 16 had a CD4 count recorded
around the time of relapse, with a median count of 137 cells/uL
(IQR 80-255).
Accounting for competing risks, the estimated risk of relapse
decreased to 16.1% at one year, 20.4% by two years and 25.9% by
four years. The main findings remained unchanged by the other
sensitivity analyses (Table 5).
Long-term Outcomes of AmBisome for HIV-VL Co-infection in India
PLOS Neglected Tropical Diseases | www.plosntds.org 5 August 2014 | Volume 8 | Issue 8 | e3053
Table 1. Demographic and clinical admission characteristics of HIV-positive patients treated for VL and patients not known to be
HIV-positive.
HIV-VL N=159
Remaining cohort
N=8590
Variable* N % N % RR (95%CI) P value
Sex (n=8749)
Male 132 83.0 4868 56.7 3.7 (2.4–5.5) ,0.001
Female 27 17.0 3722 43.3 1
Age group (years) (n =8749)
,14 5 3.1 3686 42.9 0.02 (0.01–0.05) ,0.001
14–,25 4 2.5 1539 17.9 0.04 (0.02–0.1) ,0.001
25–,35 49 30.8 1193 13.9 0.6 (0.4–0.9) 0.01
35–,45 64 40.3 945 11.0 1
45–,55 27 17.0 596 6.9 0.7 (0.4–1.1) 0.09
$55 10 6.3 631 7.3 0.3 (0.1–0.5) ,0.001
Caste (n=8695)
Scheduled Caste 22 14.1 2502 29.3 0.3 (0.8–1.9) ,0.001
Other Backward Class 89 57.1 4722 55.3 0.6 (0.4–0.8) 0.001
General Category 45 28.8 1315 15.4 1
Hemoglobin (g/dl) (n = 8715)
,6 22 14.2 1112 13.0 1.2 (0.8–1.9) 0.425
6–8 58 37.4 2841 33.2 1.3 (0.9–1.8) 0.199
.8 75 48.4 4604 53.8 1
CD4 count, cells/uL (n =122)**
,100 56 45.9 - - - -
100–199 36 29.5 - - - -
200–349 23 18.9 - - - -
$350 7 5.7 - - - -
Time from symptoms onset to diagnosis (n =8738)
.8 weeks 45 29.4 1459 17.0 1.7 (1.02–2.7) 0.04
.4–8 weeks 41 26.8 2108 24.6 1.1 (0.6–1.8) 0.813
.2–4 weeks 43 28.1 3706 43.2 0.6 (0.4–1.05) 0.07
#2 weeks 24 15.7 1312 15.3 1
History of previous treatment for VL (n =8749)
Yes 70 40.0 325 3.8 16.6 (12.4–22.4) ,0.001
No 89 56.0 8265 96.2 1
Spleen size, cm (n=8741)
.6 82 52.9 2936 34.2 2.2(1.3–3.7) 0.004
3–6 57 36.8 4395 55.2 1.02(0.6–1.8) 0.952
,3 16 10.3 1255 14.6 1
Nutrition status (n=7252)
SAM 37 23.9 1270 17.9 1.4(0.95–2.0) 0.095
MAM 30 19.4 1623 22.9 0.9(0.6–1.3) 0.56
Normal 88 56.8 4204 59.2 1
* Where n,8749, this is due to missing data.
** Window 6 months prior to VL treatment until 6 weeks after.
VL – Visceral Leishmaniasis; HIV – Human Immunodeficiency Virus; SAM – Severe Acute Malnutrition; MAM – Moderate Acute Malnutrition; RR – Relative Risk; CI – Confidence
Interval.
doi:10.1371/journal.pntd.0003053.t001
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Discussion
This study describes the admission characteristics and long-term
VL treatment outcomes for the largest cohort of HIV-VL co-
infected patients from the Indian subcontinent, with a longer
follow-up period and lower rate of loss-to-follow-up than any
report published to date. As in previous studies, our data show
high mortality in these patients, particularly in the early period
following diagnosis, and a high VL relapse rate, findings which
underscore the crucial importance of early diagnosis and
intervention for both diseases.
Early initiation of ART had a clear impact on reducing
mortality and relapse, and should therefore be considered a key
intervention in the management of these patients. In agreement
with our earlier estimates of 2-year outcomes for the first 55 HIV-
VL patients in this cohort [23], outcomes for this much larger
number of co-infected patients were substantially worse than for
VL patients not known to be HIV-positive: after receiving the
same VL treatment in the same setting, estimated all-cause
mortality and relapse rates at 15 months for patients not known to
be HIV positive were 2.8% and 1.2% respectively [18], compared
to 18.1% and 16.1% at 12 months respectively for co-infected
patients reported in this study.
Concurrent infection with tuberculosis and hemoglobin ,7 g/
dl were independently associated with mortality. In terms of
protective factors, ART initiated immediately following VL
Figure 2. Censored Kaplan Meier curve showing the cumulative hazard of death over time following discharge.
doi:10.1371/journal.pntd.0003053.g002
Table 2. Univariate analysis to determine risk factors for mortality in VL/HIV co-infection.
Variable Crude HR (95% CI) P-value
Male sex 1.16 (0.45–2.98) 0.76
Age .40 years 1.60 (0.81–3.18) 0.17
TB diagnosis* 4.24 (1.75–10.24) 0.001
History of VL* 0.81 (0.41–1.59) 0.53
Spleen size .10 cm* 0.86 (0.30–2.49) 0.79
BMI,16 kg/m2* 2.06 (1.04–4.10) 0.039
Hemoglobin ,7 g/dL* 2.55 (1.31–4.99) 0.006
CD4 count ,50 cells/mL* 1.30 (0.60–2.80) 0.51
On ART at VL diagnosisa 0.26 (0.07–0.93) 0.038
ART started after VL diagnosisa 0.29 (0.12–0.68) 0.004
* at time of VL diagnosis;
aCompared to those never started on ART.
VL – Visceral Leishmaniasis; HIV – Human Immunodeficiency Virus; BMI – Body Mass Index; HR – Hazard Ratio; CI – Confidence Interval; ART –Antiretroviral Therapy, TB – tuberculosis.
doi:10.1371/journal.pntd.0003053.t002
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Table 3. Independent risk factors for mortality in VL/HIV co-infection.
Adjusted HR (95% CI) P Adjusted HR (95% CI) P
Main analysis Stepwise model Including ART
Tuberculosis* 3.92 (1.62–9.50) 0.002 3.40 (1.39–8.33) 0.007
Hemoglobin ,7 g/dL* 2.44 (1.25–4.78) 0.009 2.16 (1.09–4.28) 0.027
On ART at VL diagnosis - 0.34 (0.09–1.24) 0.10
ART initiation after VL - 0.36 (0.15–0.85) 0.021
Sensitivity analysis 1
Tuberculosis* 3.9 (1.6–9.5) 0.002 3.5 (1.4–8.5) 0.006
Hemoglobin ,7 g/dL* 2.4 (1.2–4.8) 0.010 2.2 (1.1–4.3) 0.026
On ART at VL diagnosis - 0.35 (0.10–1.28) 0.11
ART initiation after VL - 0.38 (0.16–0.90) 0.028
Sensitivity analysis 21
Age (per 5 years increase)* 1.26 (1.09–1.46) 0.002 1.28 (1.19–1.48) 0.001
BMI (per 1 kg/m2 increase)* 0.81 (0.69–0.95) 0.009 0.82 (0.69–0.98) 0.030
Hb (per 1 g/dL increase)* 0.79 (0.66–0.95) 0.011 0.82 (0.68–0.98) 0.029
On ART at VL diagnosisa - 0.34 (0.10–1.51) 0.17
ART initiation after VLa - 0.33 (0.14–0.80) 0.014
* at time of VL diagnosis;
aCompared to those never started on ART.
1Tuberculosis not retained, but borderline significant (adjusted HR: 2.5 (95% CI 1.0–6.2); P 0.053 in stepwise model).
Sensitivity analysis 1: alternative strategy to account for missing data.
Sensitivity analysis 2: continuous co-variates entered in original form (no categorization).
VL – Visceral Leishmaniasis; HIV – Human Immunodeficiency Virus; BMI – Body Mass Index; HR – Hazard Ratio; CI – Confidence Interval; ART –Antiretroviral Therapy.
doi:10.1371/journal.pntd.0003053.t003
Figure 3. Censored Kaplan Meier curve showing the cumulative hazard of relapse over time following discharge.
doi:10.1371/journal.pntd.0003053.g003
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treatment was associated with a 64–66% reduced risk of mortality
(p,0.05). Similar reductions in mortality risk for co-infected
patients adherent to ART have been reported in other studies [8].
Our data suggested that ART use prior to VL diagnosis may also
be associated with reduced mortality, but this association did not
reach statistical significance. This lack of a demonstrated effect of
prior ART could be due simply to the relatively small number of
patients, or could reflect the possibility that patients already on
ART at time of VL diagnosis may have been experiencing ART
treatment failure or more advanced disease – or conversely that
those with more favorable responses to ART may be at much
lower risk of developing VL and therefore never enroll in the
program, leading to an underestimation of the effect of ART.
Notably, baseline CD4 counts around the time of VL diagnosis
were typically very low in our cohort (mean baseline CD4 count
122 cells/ul).
Table 4. Risk factors for relapse in VL/HIV co-infection in univariate analysis.
Variable Crude HR (95% CI) P-value
Male sex 1.32 (0.39–4.41) 0.65
Age .40 years 2.29 (1.02–5.12) 0.043
Duration of illness .4 weeks 0.69 (0.30–1.60) 0.39
TB diagnosis* 1.99 (0.47–8.46) 0.35
History of VL* 0.81 (0.36–1.82) 0.61
Spleen size .10 cm* 1.36 (0.41–4.52) 0.61
BMI,16 kg/m2* 0.78 (0.28–2.17) 0.63
Hemoglobin ,7 g/dL* 0.61 (0.21–1.86) 0.38
CD4 count ,50 cells/mL* 0.73 (0.24–2.26) 0.58
On ART at VL diagnosisa 0.55 (0.15–2.09) 0.38
ART initiation during admissiona 0.24 (0.07–0.81) 0.022
ART initiation after dischargea 0.51 (0.17–1.51) 0.22
* at the time of VL diagnosis;
aCompared to those never started on ART.
VL – Visceral Leishmaniasis; HIV – Human Immunodeficiency Virus; BMI – Body Mass Index; HR – Hazard Ratio; CI – Confidence Interval; ART – combination Antiretroviral
Therapy, TB – tuberculosis.
doi:10.1371/journal.pntd.0003053.t004
Figure 4. Evolution of CD4 count* following treatment for VL in patients who relapsed compared to those who did not. Footnote:
*Timeline restricted to 3 years as subsequent data points were limited.
doi:10.1371/journal.pntd.0003053.g004
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In terms of VL relapse risk, we did not detect clear
demographic associations, in agreement with results from a
recent systematic review looking at predictors of VL relapse in
HIV-positive patients [27]. However, initiation of ART imme-
diately following VL treatment was associated with a significant
reduced risk of relapse (although not if initiated either before or
long after VL treatment), while a history of one or more previous
VL episodes at time of treatment was not. These results differ
from those seen in the meta-analysis, which concluded that ART
did not appear to reduce the risk of relapse whereas a previous
history of VL was predictive of relapse. However, other than one
from Ethiopia, all studies included in this meta-analysis were
conducted in Europe, the majority with small sample sizes and
limited follow-up periods.
The Ethiopian study alone involved VL caused by L. donovani,
as in our Indian setting. Infection with L. donovani has different
clinical implications compared to L. infantum, the causal agent in
most European and Latin American VL cases, and therefore more
relevant to HIV/VL management in India. The study found that
ART was partially protective against VL relapse, while a baseline
CD4 count of,100 cells/uL and a history of two or more relapses
were associated with increased risk of relapse [28], however
findings may have been biased by the high proportion of patients
not receiving ART who were lost to follow up. In contrast,
predicting relapses in India appears more complex as there did not
appear to be any effect of either baseline CD4 count or of previous
VL history.
Limitations of this study
This study has a number of limitations. Primarily, although
admission and VL treatment data had relatively few missing
values, data from the HIV management perspective was
incomplete; as follow-up periods extended past 3 years, the
number of available CD4 counts decreased, which prevented
further accurate modeling. Second, a larger sample size may have
yielded more precise estimates for both risk factors and measures
of outcomes. Third, the prevalence of HIV-VL co-infection
cannot be estimated from this study, since all patients were not
systematically screened for HIV, and it is likely that a substantial
number of co-infected patients were missed in the overall treated
cohort.
Another limitation was that we considered all-cause mortality in
the analysis, therefore excluding the possibility that death may
have occurred due to other causes unrelated to HIV-VL. A further
weakness is that the analysis included 5% (n= 8) of the patients
who received a 5 mg/kg higher dose of AmBisome than the
remainder. Lastly, although no initial treatment failures were seen
in patients discharged from the program, it is likely that the
routine use of ToC would have identified treatment failures that
were missed clinically. It is unclear what the value of partial
response patterns (eg partial but not complete regression of
splenomegaly) is in determining true treatment response, partic-
ularly in co-infected patients. An Ethiopian study with systematic
ToC found 32% parasitological failure in co-infected patients after
treatment with 30 mg/kg liposomal amphotericin B despite good
clinical response [29].
Co-infected patients show decreased cellular and humoral
response to Leishmania parasites and are considered difficult to
achieve a definitive cure from VL. As such, suspicion of relapse is
more challenging in co-infected patients, since these patients often
have persistent haematological abnormalities and residual hepato-
splenomegaly at the end of treatment. Indeed, worsening of these
abnormalities in the absence of fever may itself represent a new
episode of VL, and as such it is plausible that there was under-
reporting of relapse cases due to the importance given to fever in
the routine diagnosis of symptomatic VL.
Implications for patient care and national VL programs
The findings from this cohort analysis have a number of
implications for improving the outcome of HIV-VL co-infected in
India. Recent studies in the Indian subcontinent have recom-
mended increasing the routine follow-up period after VL
treatment from 6 months to 1 year [30–32]. However, for HIV-
VL co-infected patients, it appears that the risk of relapse is
greatest within 18 months following treatment, suggesting that
routine follow-up should be extended even further for co-infected
patients. Furthermore, if secondary prophylaxis is to be initiated,
this period might be the most effective phase for its use.
Achieving longer follow-up without loss of many patients will/
would require some changes to current practice, since maintaining
long-term contact with patients who complete treatment is not
integrated into existing VL programs, and without an existing
Table 5. Independent risk factors for relapse in VL/HIV co-infection.
Adjusted HR (95% CI) P Adjusted HR (95% CI) P
Main analysis Stepwise model Including ART
Age .40 years 2.29 (1.02–5.12) 0.043 2.20 (0.98–4.95) 0.055
On ART at VL diagnosisa - 0.54 (0.14–2.04) 0.36
ART initiation during admissiona - 0.25 (0.07–0.84) 0.026
ART initiation after dischargea 0.52 (0.18–1.56) 0.25
Sensitivity analysis 21
Age (per 5 years increase) 1.24 (1.04–1.48) 0.018 1.22 (1.03–1.45) 0.021
On ART at VL diagnosisa - 0.52 (0.14–1.98) 0.34
ART initiation during admissiona 0.24 (0.07–0.80) 0.020
ART initiation after dischargea - 0.50 (0.17–1.47) 0.20
aCompared to those never started on ART.
1Sensitivity analysis 1 (not shown) yielded exactly the same results as the main analysis since there were no missing data for the variables included.
Sensitivity analysis 2: continuous co-variates entered in original form (no categorization).
VL – Visceral Leishmaniasis; HIV – Human Immunodeficiency Virus; HR – Hazard Ratio; CI – Confidence Interval; ART –Antiretroviral Therapy.
doi:10.1371/journal.pntd.0003053.t005
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framework, requires significant effort and resources. Similarly,
there are no established mechanisms for sharing information about
co-infected patients between the vertical VL and HIV programs in
India. If such mechanisms were developed, they could facilitate
more robust longer-term patient management, as has been seen in
other co-infections, such as HIV/TB.
Although routine PICT for VL patients is recommended by
WHO in areas where HIV counseling and access to ART are
available [17], this service is lacking across the majority of endemic
areas in India and is not included in the national VL program
guidelines. Conversely, screening for VL in HIV-infected patients
who have spent a significant amount of time in VL endemic areas
is not mentioned by existing National AIDS Control Organisation
(NACO) guidelines. We suggest that directives encouraging early
diagnosis of co-infection are crucial as a means of reducing the
high early levels of mortality observed in this study.
NACO guidelines recommend initiation of ART in all patients
with clinical stage IV disease irrespective of CD4 count. However
this recommendation refers to WHO guidelines, which identify
‘atypical disseminated visceral leishmaniasis’ as a stage IV defining
opportunistic infection [33], rather than simply ‘visceral leish-
maniasis’. This leads to confusion in the field when making
decisions to start ART in co-infected patients, considering the
WHO expert committee on VL clearly identifies HIV-VL co-
infection as an AIDS defining illness [1]. Simultaneously, in the
absence of national guidelines, maintaining consistent health
messaging between parallel programs for HIV and VL is
challenging. Reported non-adherence to ART regimens in India
varies considerably, from 14%–86% [34]; in this study, 23 (14.9%)
of patients either chose to discontinue, died prior to starting or did
not start ART despite being referred to appropriate care
providers. The provision of field-based guidance and training for
the management of HIV-VL co-infection, as already exists for
HIV-TB co-infection [35,36], could be of great benefit in raising
health provider awareness and improving management of these
patients.
Treatment challenges
This study suggests that 20–25 mg/kg liposomal amphotericin
B is a well-tolerated and relatively effective treatment for HIV-VL
co-infection in the Indian setting. However, these patients have a
high risk of relapse, and clearly, repeated treatment with mono-
therapy in cases of relapse may not be ideal as it may contribute to
decreased drug susceptibility in the parasite [37]. Mechanisms for
resistance to amphotericin B in clinical isolates of L. donovani
have already been described [38], and decreased efficacy observed
in co-infected patients after several treatment cycles [39,40].
Additionally, unresponsiveness to liposomal amphotericin B
seemed to develop rapidly in co-infected patients In Ethiopia
where parasitological failure rates were 16% in primary HIV-VL,
and 57% in relapse HIV-VL previously treated with AmBisome
[29]. However, to date no parasite strains resistant to liposomal
amphotericin B have been found, suggesting host-related factors
may play a more important role in treatment unresponsiveness
than parasite resistance. Although higher dose combination
therapy has been recommended in cases of multiple VL relapse
in co-infected patients [8] and has been successfully used in India
[41], the use of such combinations needs to be further evaluated in
the Indian subcontinent for all HIV-VL co-infected patients.
Within the field of TB-HIV co-infection, over the last 15 years
there have been a number of observational studies conducted to
understand the effect of ART on TB mortality, and the effect of
timing of ART initiation. Combined, these allowed a clearer
picture to emerge, which in turn contributed to the design of
several clinical trials on the subject. In the absence of other studies
from the Indian subcontinent within the field of HIV-VL co-
infection, the data from this program constitutes a clear step
forward, however highlights the need for additional studies to
consolidate the evidence base and allow triangulation of different
study findings.
Like patients with Post Kala-Azar Dermal Leishmaniasis
(PKDL), HIV-VL patients harbor chronic infection, often have
very high parasite loads and are therefore potential long-standing
reservoirs for VL transmission. The role of asymptomatic VL
infection has not yet been definitively established [42], however it
is likely that an increase in HIV prevalence in endemic areas will
lead to an associated increase in symptomatic VL infections. As
such the importance of early identification, appropriate treatment,
multidisciplinary management and follow-up of HIV-VL co-
infected patients should be considered a public health priority if
the goal of VL elimination is to be realized [43].
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